MNKD May 2024 4.500 call
| Previous Close | 0.1500 |
| Open | 0.1900 |
| Bid | 0.0000 |
| Ask | 1.0000 |
| Strike | 4.50 |
| Expire Date | 2024-05-31 |
| Day's Range | 0.1600 - 0.2400 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 15 |
PR NewswirePulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation
Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious central nervous system and pulmonary diseases using its patented dry powder inhalation iSPERSE™ technology, today announced a series of transactions with MannKind Corporation (Nasdaq: MNKD).
GlobeNewswireMannKind to Establish Boston-Area Research & Development Foothold and Expand Portfolio of Dry Powder Inhalation Technology in Transaction With Pulmatrix
Immediate opportunity to increase capacity for formulation and early asset development in upgraded Boston area R&D spaceNon-cash deal includes royalty-free iSPERSE™ technology license in exchange for access to MannKind’s Cricket® inhaler DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and o
ZacksMannKind (MNKD) Upgraded to Strong Buy: Here's Why
MannKind (MNKD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
